Phase II Study of Bevacizumab Plus Modified FOLFOX6 Regimen as the Salvage Treatment in Patients With Metastatic Breast Cancer
Anthracyclines and taxanes are the most frequently used agents for breast cancer,both in
adjuvant and in first-line metastatic settings.For the patients who do not respond or
relapse early after the administration of a taxane or anthracycline regimen,it is clearly
needed to explore new combinations and schedules of drugs.Oxaliplatin has shown very
promising activity in MBC either in monotherapy or in combination with 5-fluorouracil(5-FU)
with or without leucovorin (LV). Avastin is a target therapy with proven efficacy in the
treatment of MBC. Avastin plus FOLFOX regimen showed synergetic effet and been used as the
standard trial in metastatic colorectal cancer patients. Based on the above reason, we
initiate this phase II study to evaluate efficacy and safety of avastin plus modified
FOLFOX6 regimen in HER-2 negative metastatic breast cancer patients.
Interventional
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Progression free survival
response evaluation every two cycles
No
Xichun Hu, PhD
Principal Investigator
Medical Oncology Department
China: Ethics Committee
Fudan BR2012-11
NCT01658033
May 2012
December 2014
Name | Location |
---|